Dorsey Wright & Associates Has $3.56 Million Stake in Vertex Pharmaceuticals Incorporated (VRTX)
Dorsey Wright & Associates lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 86.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,430 shares of the pharmaceutical company’s stock after buying an additional 10,830 shares during the period. Dorsey Wright & Associates’ holdings in Vertex Pharmaceuticals were worth $3,562,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Smithfield Trust Co. bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth approximately $135,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Vertex Pharmaceuticals by 15.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after buying an additional 132 shares in the last quarter. FNY Partners Fund LP lifted its stake in shares of Vertex Pharmaceuticals by 900.0% in the second quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after buying an additional 900 shares in the last quarter. Intact Investment Management Inc. bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth approximately $213,000. Finally, Dupont Capital Management Corp bought a new position in shares of Vertex Pharmaceuticals in the second quarter worth approximately $186,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.
In related news, EVP Stuart A. Arbuckle sold 4,250 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $148.17, for a total value of $629,722.50. Following the transaction, the executive vice president now owns 46,202 shares of the company’s stock, valued at approximately $6,845,750.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Sangeeta N. Bhatia sold 7,073 shares of the firm’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $143.05, for a total transaction of $1,011,792.65. Following the completion of the transaction, the director now directly owns 11,026 shares in the company, valued at approximately $1,577,269.30. The disclosure for this sale can be found here. Insiders sold a total of 220,094 shares of company stock worth $32,074,719 in the last ninety days. 1.80% of the stock is currently owned by insiders.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded down $0.71 on Tuesday, hitting $148.03. 743,600 shares of the stock traded hands, compared to its average volume of 1,824,147. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The stock has a market capitalization of $37,616.77, a P/E ratio of 247.90, a P/E/G ratio of 3.78 and a beta of 1.63. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. During the same quarter in the prior year, the firm posted $0.16 earnings per share. The business’s revenue for the quarter was up 39.7% on a year-over-year basis. sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current year.
VRTX has been the subject of several research reports. Stifel Nicolaus boosted their price objective on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. J P Morgan Chase & Co set a $184.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. Raymond James Financial, Inc. raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 price objective for the company in a report on Wednesday, July 19th. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, Vetr cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 target price for the company. in a report on Monday, September 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have given a buy rating to the stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $173.15.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.